GFM
ARTV

GF Fund Management’s Artiva Biotherapeutics ARTV Stock Holding History

GF Fund Management’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-510
Closed -$1.46K – 704
2025
Q3 		$1.46K Sell
510
-93
-15% -$249 ﹤0.01% 627
2025
Q2 		$911 Hold
603
– – ﹤0.01% 655
2025
Q1 		$1.81K Buy
603
+93
+18% +$502 ﹤0.01% 653
2024
Q4 		$5.14K Buy
+510
New +$6.13K ﹤0.01% 611

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
Revelation Capital Management Sausalito, California $67.4M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

GF Fund Management's ARTV Position: Q4 2025 in Review

GF Fund Management sold out of Artiva Biotherapeutics (ARTV) in Q4 2025, closing a stake of 510 shares — an estimated $1.46K sold.

GF Fund Management first reported a position in ARTV in Q4 2024 and held it in 4 quarters. The position peaked at $5.14K in Q4 2024. 34 funds tracked by Wall St. Rank hold ARTV as of Q4 2025.

  • GF Fund Management reported no remaining Artiva Biotherapeutics position as of Q4 2025 after selling out during the quarter.
  • GF Fund Management sold 510 Artiva Biotherapeutics shares in Q4 2025, an estimated $1.46K.
  • GF Fund Management first reported a position in Artiva Biotherapeutics in Q4 2024 and held it in 4 quarters.
  • GF Fund Management's Artiva Biotherapeutics position peaked at $5.14K in Q4 2024.
  • 34 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q4 2025.

Based on GF Fund Management's 13F filing for Q4 2025, filed 27 Jan 2026.